[go: up one dir, main page]

PL3352735T3 - Formulacje olanzapiny o przedłużonym uwalnianiu - Google Patents

Formulacje olanzapiny o przedłużonym uwalnianiu

Info

Publication number
PL3352735T3
PL3352735T3 PL16775424.1T PL16775424T PL3352735T3 PL 3352735 T3 PL3352735 T3 PL 3352735T3 PL 16775424 T PL16775424 T PL 16775424T PL 3352735 T3 PL3352735 T3 PL 3352735T3
Authority
PL
Poland
Prior art keywords
sustained release
olanzapine formulations
release olanzapine
formulations
sustained
Prior art date
Application number
PL16775424.1T
Other languages
English (en)
Inventor
Mark Alan Smith
Carine CLAASSEN-PUNT
Original Assignee
Teva Pharmaceuticals International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International Gmbh filed Critical Teva Pharmaceuticals International Gmbh
Publication of PL3352735T3 publication Critical patent/PL3352735T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)
PL16775424.1T 2015-09-21 2016-09-21 Formulacje olanzapiny o przedłużonym uwalnianiu PL3352735T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
PL3352735T3 true PL3352735T3 (pl) 2024-01-29

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16775424.1T PL3352735T3 (pl) 2015-09-21 2016-09-21 Formulacje olanzapiny o przedłużonym uwalnianiu

Country Status (22)

Country Link
US (4) US20170079985A1 (pl)
EP (2) EP3352735B1 (pl)
JP (2) JP2018527397A (pl)
KR (1) KR20180054627A (pl)
CN (2) CN108289834A (pl)
AR (1) AR106085A1 (pl)
AU (2) AU2016328958B2 (pl)
CA (1) CA2998504C (pl)
CL (1) CL2018000727A1 (pl)
DK (1) DK3352735T3 (pl)
EA (1) EA201890788A1 (pl)
ES (1) ES2960753T3 (pl)
FI (1) FI3352735T3 (pl)
HK (1) HK1255946A1 (pl)
HU (1) HUE063850T2 (pl)
IL (3) IL295161A (pl)
MX (2) MX2018003380A (pl)
NZ (1) NZ740665A (pl)
PL (1) PL3352735T3 (pl)
PT (1) PT3352735T (pl)
TW (1) TWI798161B (pl)
WO (1) WO2017053346A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR20200118034A (ko) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 올란자핀의 비강내 전달
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CN1239158C (zh) * 1997-09-30 2006-02-01 伊莱利利公司 2－甲基－噻吩并－苯并二氮杂䓬制剂
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN101862455A (zh) 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送系统
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US20080193542A1 (en) * 2005-04-13 2008-08-14 Pfizer Inc. Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions
WO2006109177A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
PL1921919T3 (pl) * 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
EP2054073B1 (en) 2006-07-11 2014-11-26 Foresee Pharmaceuticals, Inc. Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
JP5302952B2 (ja) 2007-04-19 2013-10-02 ドン・ア・ファーム・カンパニー・リミテッド 糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
JP5951991B2 (ja) 2008-08-12 2016-07-13 ノバルティス アーゲー 医薬組成物
EP2355853B1 (en) 2008-10-10 2016-12-07 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
WO2010105093A2 (en) 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
CA2784394C (en) 2010-01-04 2016-12-13 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
EP3257498B1 (en) 2010-12-29 2019-04-24 Medincell Biodegradable drug delivery compositions
CN103945865B (zh) 2011-06-10 2016-10-26 拉姆斯科股份有限公司 用于将蛋白质递送至眼睛的缓释制剂及其制备方法
HUE035214T2 (hu) 2011-10-24 2018-05-02 Braeburn Pharmaceuticals Inc Beültethetõ hatóanyag adagoló készítmények és az ezekkel végzett kezelési eljárás
KR20220044379A (ko) 2012-01-23 2022-04-07 알러간, 인코포레이티드 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
HUE036141T2 (hu) 2013-06-20 2018-06-28 Pharmathen Sa Szigmoid kibocsátási profillal bíró polilaktid-poliglikolid mikrorészecskék elõállítása
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
EP4331570A1 (en) 2024-03-06
WO2017053346A1 (en) 2017-03-30
US20220323458A1 (en) 2022-10-13
HK1255946A1 (zh) 2019-09-06
EP3352735A1 (en) 2018-08-01
AU2016328958B2 (en) 2022-04-21
CA2998504C (en) 2023-06-20
KR20180054627A (ko) 2018-05-24
AR106085A1 (es) 2017-12-13
CA2998504A1 (en) 2017-03-30
CN108289834A (zh) 2018-07-17
MX2022007315A (es) 2022-07-13
AU2016328958A1 (en) 2018-04-05
CN116942677A (zh) 2023-10-27
IL295161A (en) 2022-09-01
TWI798161B (zh) 2023-04-11
EA201890788A1 (ru) 2018-09-28
US20180264001A1 (en) 2018-09-20
TW201726144A (zh) 2017-08-01
ES2960753T3 (es) 2024-03-06
NZ740665A (en) 2023-04-28
JP2018527397A (ja) 2018-09-20
DK3352735T3 (da) 2023-10-30
CL2018000727A1 (es) 2018-09-28
JP2021167331A (ja) 2021-10-21
MX2018003380A (es) 2018-08-16
IL258086A (en) 2018-05-31
US20240238307A1 (en) 2024-07-18
EP3352735B1 (en) 2023-08-30
US20170079985A1 (en) 2017-03-23
HUE063850T2 (hu) 2024-02-28
FI3352735T3 (fi) 2023-10-20
IL275735A (en) 2020-08-31
AU2022206695A1 (en) 2022-08-11
PT3352735T (pt) 2023-10-30

Similar Documents

Publication Publication Date Title
ES3007987T3 (en) Pharmaceutical formulations
IL265609A (en) New formulations
HK1254343A1 (zh) 藥物製劑
HK1258718A1 (zh) 控釋製劑
HK1258803A1 (zh) 賴諾普利製劑
GB201607918D0 (en) Novel formulations
GB201404139D0 (en) Sustained release buprenorphine solution formulations
ZA201704263B (en) Controlled-release formulations
AU366777S (en) Pessary
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
HK1244714A1 (zh) 阿普斯特緩釋製劑
IL275735A (en) Olanzapine sustained release pharmaceutical preparation
IL258852A (en) Preparations for delayed release of local anesthetics
HK1252549A1 (zh) 控釋tozadenant製劑
HK1248102A1 (zh) 三脈衝釋放興奮劑製劑
IL247828A0 (en) Progesterone compounds
IL269403A (en) Olanzapine sustained release pharmaceutical preparation
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201617866D0 (en) Novel formulations